Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.05
May 16, 2022 6:54 AM EDTProtalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $15.5 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
... More